01—Abstract
Summary
Summary of the 8-K/A filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.
BD (Becton, Dickinson and Company) has permanently appointed Vitor Roque as Executive Vice President and Chief Financial Officer, effective May 7, 2026.
Roque had served as interim CFO since December 5, 2025, and has been with BD for more than 25 years, most recently as Senior Vice President of Finance and Corporate Financial Planning and Analysis. The filing is an amendment (8-K/A) to the October 15, 2025 8-K that first disclosed his interim appointment, and it adds the compensation terms for his permanent role. The leadership decision removes the uncertainty of an interim CFO during a period of portfolio change.
The company credits Roque with leading the global finance function during the separation of the Biosciences & Diagnostic Solutions business, which it says was completed ahead of schedule. His compensation package is set at a $770,000a annual base salary, a target bonus of 95% of base salary (pro-rated for fiscal year ending September 30, 2026), and an annual equity award target value of $3,000,000. He also receives a one-time $250,000 cash payment and a $250,000 time-vested unit grant to recognize his interim service.
Equity awards vest subject to continued service and the terms of the 2004 Employee and Director Equity-Based Compensation Plan. Roque will also sign a change-of-control agreement guaranteeing two years of continued employment following a change of control, with a severance multiple of two times salary and bonus, consistent with other executive officers' agreements. For investors, the filing signals management continuity and a conventional executive pay structure, with no unusual or outsized terms disclosed.
The disclosed amounts are modest relative to BD's scale, and the filing itself contains no financial results, guidance, or changes to BD's operating outlook. Investors should treat this as a governance and retention update rather than a material change to the company's financial profile.
02—Key points
Key Highlights
- Vitor Roque, interim CFO since December 2025, was appointed permanent Executive Vice President and Chief Financial Officer effective May 7, 2026.
- Roque's annual base salary is set at $770,000, with a target bonus of 95% of base salary, pro-rated for the fiscal year ending September 30, 2026.
- Annual equity award target value is $3,000,000, subject to continued service and the 2004 Plan's terms.
- A one-time $250,000 cash payment and a $250,000 time-vested unit grant recognize his service as interim CFO.
- Roque will enter a change-of-control agreement providing two years of continued employment and a severance multiple of 2x salary and bonus, in line with other executive officers.
- The company credits Roque with leading the global finance function during the separation of the Biosciences & Diagnostic Solutions business, which it states was completed ahead of schedule.
- The filing is an 8-K/A amending the October 15, 2025 8-K and contains no new financial results, guidance, or operating updates.
03—Questions
Frequently Asked Questions
Who is BD's new Chief Financial Officer and what is his background?
Vitor Roque, who served as interim CFO from December 2025, is now the permanent Executive Vice President and CFO. He has more than 25 years at BD and most recently served as Senior Vice President of Finance and Corporate Financial Planning and Analysis, with prior senior finance and operations roles across manufacturing, regions, and business units.
What is Roque's compensation package?
His annual base salary is $770,000, with an annual target bonus of 95% of salary (pro-rated for fiscal 2026) and an annual equity award target value of $3,000,000. He also receives a one-time $250,000 cash payment and a $250,000 time-vested unit grant for his interim service.
Does the filing include any severance or change-of-control protections?
Yes. Roque will sign an agreement providing for two years of continued employment following a change of control, with a severance multiple of two times salary and bonus. The company says these terms are similar to agreements previously disclosed for other executive officers.
Does this announcement change BD's financial outlook?
No. The filing covers only a leadership appointment and compensation terms. It contains no new financial results, guidance, or operating updates, so investors should look to BD's earnings reports and guidance for changes to the financial outlook.
Why was this filed as an amendment?
The October 15, 2025 8-K reported Roque's interim appointment effective December 5, 2025. This 8-K/A updates Item 5.02 to report his permanent appointment and the compensation approved by the Compensation and Human Capital Committee effective May 7, 2026.
04—Continue